Millions of people know GLP-1 medications as powerful weight-loss drugs, but researchers are uncovering a much bigger and more complicated story about what these medicines may do inside the body.
11% of American adults are currently taking GLP-1 medications for weight loss alone, according to Gallup, and that number does not include people using them for diabetes or other medical conditions. Although the drug class has been used clinically for about two decades, medications like Ozempic and Wegovy have recently become symbols of a much broader conversation about health, disease prevention, and the future of medicine.
The biggest question now is no longer just how much weight these drugs can help people lose. Researchers are investigating whether GLP-1 medications may also affect conditions involving the heart, kidneys, liver, sleep, addiction and even cancer risk.
Some of those findings have already changed medical practice, while others remain early-stage research that requires much more evidence. Understanding the difference is becoming increasingly important as excitement around these medications continues to grow.
More Than an Appetite Drug
These medications work on far more of the body than most people realize. That’s a significant part of why researchers keep finding effects beyond weight loss.
GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by the small intestine after eating. It helps trigger insulin production, slows food movement through the stomach, and signals the brain that the body has had enough food. GLP-1 medications mimic that hormone, but their effects may extend beyond appetite control.
That is because GLP-1 receptors are found throughout the body, including in the brain, heart, kidneys, blood vessels, lungs and thyroid. Researchers believe this wide distribution helps explain why the medications are being studied for conditions far beyond obesity and diabetes.
Dr. Robert Kushner, founder of the American Board of Obesity Medicine, described the broader impact of the drug class by pointing to “a range of systemic health benefits of GLP-1 medications that are linked to their anti-inflammatory properties, metabolic enhancement and mechanical benefits.”
The medications first became important as diabetes treatments roughly 20 years ago. The current scientific focus is on understanding how many other systems they may influence.
What the Science Has Already Established
Some benefits associated with GLP-1 medications are no longer just theories. Several uses have already received FDA approval.
Heart health was one of the earliest areas where the conversation expanded. Wegovy is approved to reduce the risk of heart attack and stroke in adults with established heart disease and excess weight. At the same time, Ozempic has a similar approval for people with Type 2 diabetes and kidney disease.
Sleep apnea became another major development when Zepbound became the first FDA-approved medication for obstructive sleep apnea. Clinical trials showed meaningful reductions in breathing disruptions among people taking the drug.
The list has continued to grow. Ozempic is now approved to reduce the risk of worsening chronic kidney disease and cardiovascular death in certain patients. Wegovy is also approved for metabolic dysfunction-associated steatohepatitis, known as MASH, in adults with moderate-to-advanced fibrosis.
Scientists are still debating how much of these improvements come from weight loss itself and how much comes from other biological effects. A study co-authored by Dr. Harlan Krumholz of Yale found tirzepatide lowered systolic blood pressure by nearly seven points compared with placebo. Other research found semaglutide reduced cardiovascular inflammation even among people who had not experienced major weight loss.
“The weight loss is not fully explaining what’s going on,” Krumholz said to Today. “The benefits of these GLP-1s extend beyond the weight loss.”
The Cancer Numbers Are Striking, But Researchers Are Being Careful
Early studies have produced attention-grabbing results, but scientists warn that promising associations are not proof.
A 2026 study linked GLP-1 use with a 41% lower risk of developing obesity-related cancers among non-diabetic patients taking the medications for weight loss. Another study presented at the 2026 American Society of Clinical Oncology annual meeting found that women with excess weight who used GLP-1 medications were about 30 percent less likely to develop breast cancer than nonusers.
Save this article
Enter your email address and we'll send it straight to your inbox.
Those findings have generated interest, but researchers are emphasizing caution.
Researchers behind the 2026 cancer study also noted that reducing cancer risk should not currently be a standalone reason to prescribe GLP-1 medications.
Dr. Elizabeth McDonald, who led the breast cancer research, described the findings as a reason for further investigation rather than a final answer. The drugs affect “many different targets and pathways associated with cancer development,” she said. “So we’re eager to study them in this context.”
Related: 7 Common Weight Loss Myths You Should Stop Believing
The Addiction Finding Nobody Expected
People taking GLP-1 medications for diabetes and weight loss began reporting unexpected changes, including reduced alcohol cravings, fewer cigarette urges and less desire for certain compulsive behaviors.
Researchers began studying the pattern more formally. Clinical trials found GLP-1 medications may reduce alcohol cravings and consumption in controlled settings. In contrast, research involving veterans with Type 2 diabetes found GLP-1 use was consistently associated with lower risks across several substance-use disorders.
GLP-1 medications are not FDA-approved treatments for substance-use disorders. Any future role would likely be considered alongside established approaches such as therapy, peer support, and comprehensive addiction care.
Side Effects, Costs and the Questions That Remain
The excitement around GLP-1 medications is real, but so are the unanswered questions about long-term use.
The most commonly reported side effects involve the digestive system, including nausea, stomach pain, diarrhea, constipation and vomiting. More serious potential concerns include thyroid tumors, pancreatitis, and gallbladder problems. Some patients have also reported muscle loss, possible vision changes, and emotional effects sometimes described as an “Ozempic personality,” involving reduced pleasure or emotional engagement.
Access remains another challenge. Cost and insurance coverage continue to limit availability, especially when GLP-1 medications are being considered for conditions beyond their current approvals.
Kushner identified one of medicine’s biggest remaining questions: “which patients benefit most, at what dose and for how long.”
GLP-1 medications have moved from being viewed primarily as diabetes and weight-loss drugs to becoming one of the most closely studied drug classes in modern medicine. Whether they eventually transform care across multiple diseases will depend on what researchers discover next.
Have you or someone close to you taken a GLP-1 medication and noticed effects beyond the original reason for taking it?
More Articles You Might Be Interested in:
- Dr. Oz Backs GLP-1 Weight-Loss Drugs as Obesity Crisis Drives U.S. Chronic Disease Costs
- Nestlé Is Developing New Products for Weight Loss Drug Users as GLP-1 Drugs Change How People Eat
- Can you take Ozempic, Wegovy or Zepbound if you have IBS?
